Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763236
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituitary AdenomasTomislav FelbabićCompletedNot Applicable
NCT07763236Completed
Not Applicable
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituit...Tomislav Felbabić
NCT07762482
Periodontal Tissue Stability After Surgical Correction of Altered Passive EruptionUniversity of Sao PauloRecruitingNot Applicable
NCT07762482Recruiting
Not Applicable
Periodontal Tissue Stability After Surgical Correction of Altered Passive Erupti...University of Sao Paulo
NCT07762859
Wearable Ambulatory Vs. Office BP in HemodialysisGangnam Severance HospitalNot Yet RecruitingNot Applicable
NCT07762859Not Yet Recruiting
Not Applicable
Wearable Ambulatory Vs. Office BP in HemodialysisGangnam Severance Hospita...
NCT07764003
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsHangzhou Highlightll Pharmaceutical Co., LtdNot Yet RecruitingPhase 2
NCT07764003Not Yet Recruiting
Phase 2
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Re...Hangzhou Highlightll Phar...
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07762833
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisGalderma R&DNot Yet RecruitingPhase 3
NCT07762833Not Yet Recruiting
Phase 3
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub...Galderma R&D
NCT07762144
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third HospitalEnrolling By Invitation
NCT07762144Enrolling By Invitation
—
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third H...
NCT07764107
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy DeviceNational Health Research Institutes, TaiwanNot Yet RecruitingNot Applicable
NCT07764107Not Yet Recruiting
Not Applicable
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-...National Health Research...
NCT07764198
A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult AmblyopiaJiannan HuangRecruitingNot Applicable
NCT07764198Recruiting
Not Applicable
A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Ambly...Jiannan Huang
NCT07761949
Assessing the Impact of Streetscape Exposure on Children's PerceptionZhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruiting
NCT07761949Recruiting
—
Assessing the Impact of Streetscape Exposure on Children's PerceptionZhongshan Ophthalmic Cent...
NCT07763184
mNGS for IFD in Patients With Hematological MalignanciesNanfang Hospital, Southern Medical UniversityNot Yet Recruiting
NCT07763184Not Yet Recruiting
—
mNGS for IFD in Patients With Hematological MalignanciesNanfang Hospital, Souther...
NCT07762326
Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple SclerosisCairo UniversityNot Yet RecruitingNot Applicable
NCT07762326Not Yet Recruiting
Not Applicable
Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders an...Cairo University
NCT07763626
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of GenovaCompletedNot Applicable
NCT07763626Completed
Not Applicable
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of Genova
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07764341
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology CenterNot Yet RecruitingNot Applicable
NCT07764341Not Yet Recruiting
Not Applicable
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology Center
NCT07763899
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763899Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762820
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder TumorsLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07762820Not Yet Recruiting
Not Applicable
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retr...Ludwig-Maximilians - Univ...
Result Breakdown
Not yet recruiting11 (55%)
Completed4 (20%)
Recruiting4 (20%)
Enrolling by invitation1 (5%)
not_applicable12 (60%)
Not Specified3 (15%)
Phase 42 (10%)
Phase 21 (5%)
Phase 11 (5%)
Phase 31 (5%)